8-K: Apyx Medical Raises $10M in Public Stock Offering

Apyx Medical Corporation announced the pricing and closing of an underwritten public offering of 2.76 million common shares, raising approximately $9.4 million in net proceeds for working capital and general corporate purposes.

Summary

• Apyx Medical Corporation completed an underwritten public offering of 2,762,431 shares of its common stock.
• The shares were priced at $3.62 per share.
• The company granted the underwriter, Lucid Capital Markets, LLC, a 45-day option to purchase up to an additional 414,365 shares.
• The aggregate gross proceeds to the company from the offering are approximately $9.4 million, after deducting a 6.0% underwriting discount but before other offering expenses.
• Net proceeds are intended for working capital, general corporate purposes, expanding sales and marketing, capital expenditures, acquisitions of complementary businesses, products, or technologies, and repaying indebtedness.
• The offering closed on November 19, 2025.

Sentiment

Score: 7

Explanation: The successful completion of a capital raise provides the company with necessary funds for growth and operational stability, which is generally positive. However, the dilution for existing shareholders and the absence of specific financial performance updates temper the overall sentiment. The stated use of proceeds for growth initiatives is a positive signal for future prospects.

Positives

• Successful completion of a public offering, securing capital for operational and strategic initiatives.
• The capital raise provides funding for working capital, sales and marketing expansion, capital expenditures, and potential acquisitions.
• The offering strengthens the company's financial position by providing funds for general corporate purposes and debt repayment.

Negatives

• The offering involves dilution for existing shareholders due to the issuance of new common stock.
• The underwriting discount of 6.0% reduces the gross proceeds received by the company.
• The company is restricted from issuing additional common stock or common stock equivalents for 90 days post-closing, limiting immediate future capital flexibility outside of specific exemptions.

Risks

• Risks related to the regulatory environment, including the ability to gain requisite approvals for products from the FDA and other governmental bodies.
• Potential for sudden or extreme volatility in commodity prices and availability, including supply chain disruptions, component shortages, manufacturing disruptions, or logistics challenges.
• Changes in general economic, business, or demographic conditions or trends.
• Changes in and effects of the geopolitical environment.
• Liabilities and costs from pending or threatened litigations, claims, disputes, or investigations.
• Risks detailed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company expects to use the net proceeds from the offering for working capital and general corporate purposes, including expanding its sales and marketing, capital expenditures, acquisitions of complementary businesses, products, or technologies, and repaying indebtedness. The company also maintains a cautionary stance on forward-looking statements, acknowledging risks related to regulatory approvals, supply chain, macroeconomic conditions, and potential litigation.

Management Comments

• Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating peoples lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring SystemTM in the cosmetic surgery market and J-Plasma in the hospital surgical market.
• Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents.
• The AYON Body Contouring SystemTM is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients.
• The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

Industry Context

This public offering by Apyx Medical Corporation, a surgical aesthetics company, indicates a strategic move to bolster its financial resources amidst a competitive and evolving medical device market. The focus on Renuvion and AYON Body Contouring System suggests continued investment in its core aesthetic and hospital surgical product lines. The capital raise could enable the company to enhance its market position through expanded sales and marketing efforts, potential acquisitions, and R&D, which are common strategies in the high-growth but capital-intensive medical aesthetics sector.

Comparison to Industry Standards

• The offering price of $3.62 per share and the 6.0% underwriting discount are within typical ranges for public offerings of this size in the medical device sector, though specific comparable companies or projects are not detailed in the filing.
• The use of proceeds for working capital, sales/marketing expansion, capital expenditures, and acquisitions aligns with common growth strategies for medical technology companies seeking to scale operations and expand product portfolios.
• The 90-day lock-up period for subsequent equity sales is a standard practice to prevent immediate dilution post-offering and stabilize the stock price.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new shares. However, the capital raise provides funds for growth initiatives, which could benefit long-term shareholder value.
• Employees: Funds for general corporate purposes, including potential expansion of sales and marketing, could lead to job creation or stability.
• Customers: Funds for capital expenditures and potential acquisitions could lead to enhanced products or services.
• Creditors: Proceeds allocated to repaying indebtedness could improve the company's credit profile.

Next Steps

• The underwriter has a 45-day option to purchase up to an additional 414,365 shares of common stock.
• The company will apply to list all newly issued shares on the Nasdaq Global Select Market.
• The company will continue to maintain its registration under the Exchange Act for three years from the execution date.
• The company will make an earnings statement generally available to security holders within 15 months following the execution date.
• The company will continue to retain a nationally recognized independent certified public accounting firm for at least three years.

Key Dates

Recommendation

The successful completion of the public offering provides Apyx Medical with a significant capital injection for working capital, strategic growth initiatives, and debt repayment. This is a positive step for the company's operational stability and future expansion, particularly in its surgical aesthetics and hospital surgical markets. However, the offering also introduces dilution for existing shareholders. While the capital infusion is beneficial, the filing does not provide new information on financial performance or specific growth catalysts that would warrant a 'buy' recommendation. The 90-day restriction on further equity sales offers some short-term stability. Investors should 'hold' to observe how the company effectively deploys these funds to execute its growth strategy and manage the inherent risks in its regulatory and competitive environment, as detailed in its SEC filings.

Keywords

Apyx Medical, APYX, Public Offering, Common Stock, Capital Raise, Underwriting Agreement, Renuvion, AYON Body Contouring System, Surgical Aesthetics, Medical Devices, Nasdaq, Equity Offering, Working Capital, Corporate Finance